Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2021

Fiore Vito, Ranieri Roberto, Dell'Isola Serena, Pontali Emanuele, Barbarini Giorgio, Prestileo Tullio, Marri Daniele, Starnini Giulio, Sotgiu Giovanni, Madeddu Giordano, Babudieri Sergio

Abstract excerpt

Inmates have higher HCV prevalence than general population, representing a fundamental step towards HCV eradication. Our aim was to compare 8-week glecaprevir/pibrentasvir treatment in a case-control study between incarcerated and free patients. Eleven Italian prisons and six outpatient clinics were involved. Patients were matched for sex, risk factors, METAVIR grade, HIV and HBV co-infections. About 131...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Feasibility Studies

Share to Lactams, Macrocyclic

Share to Prisoners

Share to Pyrrolidines

Share to Quinoxalines

Source

Identifiers

PMID: 33226730
DOI: 10.1111/liv.14745

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Feasibility and efficacy of 8 week Glecaprevir/Pibrentasvir to treat incarcerated viraemic HCV patients: A case-control study.PMID 33226730Read ↗

Glecaprevir/Pibrentasvir is safe and effective in Italian patients with chronic hepatitis C aged 75 years or older: A multicentre study.Semantic proximity Read ↗

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.Semantic proximity Read ↗

High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use.Semantic proximity Read ↗

Good results of chronic HCV management in a single centre prison population.Semantic proximity Read ↗

Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates.Semantic proximity Read ↗

Hepatitis C viral infection among prisoners.Semantic proximity Read ↗

Genotype distribution and treatment response among incarcerated drug-dependent patients with chronic hepatitis C infection.Semantic proximity Read ↗

Grazoprevir/elbasvir for the immediate treatment of recently acquired HCV genotype 1 or 4 infection in MSM.Semantic proximity Read ↗

Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.Semantic proximity Read ↗

Treatment of hepatitis C with peginterferon and ribavirin in a public health program.Semantic proximity Read ↗

Efficacy of peginterferon plus ribavirin in patients receiving opioid substitution therapy : Final results of the Austrian PegHope study.Semantic proximity Read ↗

Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.